Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (
Humira, AbbVie Ltd.), certolizumab pegol (CER) (
Cimzia, UCB Pharma SA), etanercept (ETN) (
Enbrel, Pfizer Ltd.), golimumab (GOL) (
Simponi, Janssen Biologics B.V), infliximab (IFX) (
Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (
Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (
Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd.
[
source, 2015]